AHR and fatty liver disease: Experiments performed in AHR liver-specific and inducible transgenic (TG) mice [tetracycline responsive element (TetRE)–constitutively activated human AHR (CA-AHR) TG mice] fed an obesogenic diet showed that AHR activation worsens hepatic steatosis, but inhibits diet-induced obesity and systemic insulin resistance.